A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.
Recruiting now. Registry record last updated June 5, 2024.
- Who can join
- Adults 40 to 65, have type 2 diabetes.
- What you take
- Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 3 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Diabetes Mellitus, Type 2. Also studied in: Stroke (CVA) or Transient Ischemic Attack.
Full scientific study title: Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes.
Who can join
Adults 40 to 65, have type 2 diabetes. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Men and women 40-65 years of age
- Subjects with type-2 diabetes \>= 3 years and HbA1C 7%-10% with blood sugar control medications including insulin, metformin, sulfonylureas, or SGLT2 inhibitors
- Medically stable
- Has not received any investigational drug in the past 6 months
- Willing to participate and sign informed consent.
Key exclusion criteria
- Contraindication to MRI or contrast agent
- eGFR\<45 mL/min/1.73m2 (eGFR is a measurement of kidney function)
- Currently treated with glucagon-like peptide-1 receptor antagonist (same drug class as study intervention)
- Unable to perform home-glucose monitoring
- Currently need more than 100 units of insulin daily
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Washington1 site
- University of Washington - Harborview Medical CenterSeattle, Washington
Timeline
Started enrolling: January 11, 2024. Expected completion: December 31, 2026. Last updated on ClinicalTrials.gov: June 5, 2024.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
